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OBJECTIVES: Treatment with esomeprazole or placebo was investigated in patients 
with PUB (NCT00251979). In all, 102 of 764 patients from 16 countries in Europe, 
Asia and Africa were Swedish. Following successful endoscopic hemostasis, patients 
were randomized to 72 hours intravenous esomeprazole or placebo with subsequent 
oral esomeprazole 40 mg for 27 days. Rebleeding was the primary variable and 
occurred in 7.2% and 12.9% in the esomeprazole and placebo group, respectively. 
The objective of this study was to describe hospital costs in Sweden for patients with 
and without rebleeding. METHODS: The KPP database includes 60% of all Swedish 
episodes of somatic in-hospital care and reports total hospital costs. Six out of the 12 
participating Swedish hospitals utilize KPP. Here, individual cost data was collected 
and matched with the in-hospital episode and the study deﬁ nition of rebleeding. 
RESULTS: Data was collected from all 60 patients in the six KPP reporting clinics. 
Information structure and level of detail varied considerably between clinics, why only 
total costs are reported. Six patients (10%) were deﬁ ned as rebleeders, and accounted 
for 20% of the total costs for all patients. The mean total cost/patient was SEK 39,822 
(median 29,082, range: 10,377–263,520) for all patients without rebleeding and SEK 
88,928 (median 82,273, range: 52,464–160,090) for all patients with rebleeding (c1 
= SEK9.84). The mean cost per patient without rebleeding varied between clinics from 
SEK 14,791 to 45,636. CONCLUSIONS: Hospital costs for patients with PUB vary 
considerably. The cost of patients with rebleeding was more than double that of 
patients without rebleeding, and in all the 10% of patients who rebled accounted for 
20% of the total hospital costs. In conclusion, a treatment which successfully prevents 
rebleeding is important not only from a clinical perspective, but also from a cost point 
of view to reduce hospital costs.
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OBJECTIVES: Chronic hepatitis B (CHB) treatment necessitate, according to Euro-
pean guidelines, to use potent antiviral agents with optimal resistance proﬁ les. 
Increased health care ﬁ nancial burden means physicians, payers and decision makers 
need to evaluate CHB treatment cost-effectiveness. This model aims to estimate the 
medical cost savings of treating nucleoside-naïve CHB patients with a potent antiviral 
agent, from a French payer’s perspective. METHODS: CHB was simulated using a 
disease-state transition model with states deﬁ ned as mild ﬁ brosis (Ishak F0/F1), signiﬁ cant 
ﬁ brosis (F2–F4), advanced ﬁ brosis/cirrhosis (>F4) and complicated states (decompensated 
cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplant and death) based on 
available natural history data. The model assumed a 5-year entecavir treatment and 
30-year follow-up and was based on available clinical data. The transition probabilities 
between states increased with detectable viral load levels and varied by HBeAg status. 
Direct medical costs included CHB and liver complications management. The primary 
model output is the estimated cost avoided per patient per day of treatment, compared to 
no treatment in nucleoside-naïve CHB patients. RESULTS: Progression to HCC, liver 
transplant or death was estimated at 76% for untreated patients compared to 31% 
for entecavir patients, while the progression to DC, HCC, liver transplant or post-liver 
transplant resulted in annual costs/patient of c9,718 [95% conﬁ dence interval (CI): 
8,260; 11,175], c5,066 [4,306; 5,826], c87,105 [74,039; 100,171] and c19,421 
[16,508; 22,335], for 2008, respectively. Cost of not treating CHB patients was 
estimated at c16.4/day (average over patient lifetime). Entecavir treatment translated 
into speciﬁ c patient beneﬁ t with an estimated cost saving of c1.2/day of entecavir 
treatment (95% CI: −9.6; 4.6). CONCLUSIONS: Treatment of CHB using a potent 
antiviral agent with high genetic barrier to resistance, such as entecavir, is cost-
effective as associated with improved clinical outcomes and lower health care costs 
compared with no treatment.
PGI11
RISK FACTORS AND COSTS ASSOCIATED TO NSAIDS THERAPIES IN 
ITALY: AN ADMINISTRATIVE DATABASE ANALYSIS
Berti A1, Rossi E1, Sacripanti C2, Poluzzi E2, De Rosa M1
1Cineca, Casalecchio di Reno (BO), Italy; 2Università di Bologna, Bologna, Italy
OBJECTIVES: Describe treatment patterns of NSAIDs, risk factors for gastrointestinal 
injuries and associated costs. METHODS: Prescriptions of reimbursed NSAIDs in 
2007 were selected from ARNO database and analyzed for 12 months in 23 Italian 
Local Health Units. Intensity of NSAID use and co-medications were analyzed. Cluster 
analysis and risk stratiﬁ cation were performed to assess the inﬂ uence of risk factor in 
NSAID prescriptions and gastroprotective (GP) co-medications. Risk factor analysis 
was based on prescribing limitative AIFA (Agenzia Italiana del FArmaco) note 1 for 
GP: presence of chronic NSAID treatment, age ≥60 years, concomitant antithrombot-
ics, cortisonics and/or previous gastric events. RESULTS: Among 1,028,100 new 
NSAIDs recipients (76% of overall treated) 31% received nimesulide, 33% diclofenac, 
20% ketoprofen, 13% ibuprofen, 12% COX2i and 10% piroxicam. NSAID preva-
lence appeared increased with age, whereas decreased in >80 years except for ibupro-
fen. Fifty-eight percent of patients <60 yo received <40 posologic units/year. 
Meanwhile, 62% of patients ≥60 yo received >80 posologic units/year. Patients on 
ibuprofen + COX2i seemed to have more risk factors (at least 2 risk factors consistent 
with AIFA prescribing note 1 in >33% of patients treated with COX2i or ibuprofen) 
in comparison with <30% for those treated with the other NSAIDs (P < 0.001). 
Moreover, ibuprofen, COX2i and diclofenac showed statistically signiﬁ cant higher 
frequency of GP co-medication (16%) compared to other NSAIDs, (<13%, P < 0.001). 
Drug expenditure varied among treatments. Nimesulide and COX2i were associated 
with the highest NSAIDs + GP total costs/year, respectively 167 and 212 euros. 
Despite the high frequency of GP co-medications with ibuprofen and diclofenac, lower 
expenditures were observed, 138 and 118 euros, respectively. CONCLUSIONS: This 
analysis showed that cost for gastroprotective co-medications were higher than the 
cost of NSAIDs alone. However, NSAIDs + GP expenditure differed among NSAID 
treatment groups.
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OBJECTIVES: The aim of this study was to estimate the implications of poorly 
controlled GERD for patients and the economic implications for health care providers 
and employers in Germany, Italy and Spain. METHODS: Based on population ﬁ gures, 
prevalence and incidence for GERD and its implications and cost data, the number 
of patients with poorly treated GERD and their implications, as well as the economic 
consequences for health services and employers were calculated for each country. 
RESULTS: The amount of patients with poorly treated GERD that have severe 
esophagitis are estimated to be 740,364 in Germany, 240,559 in Italy and 225, 054 
in Spain per year. The number of patients with Barrett’s oesophagus are estimated to 
be 29,678 in Spain, 19,327 in Germany and 10,079 in Italy. The number of patients 
with adenocarcinoma are around 483 patients in Germany, 142 in Spain, and 53 in 
Italy. Costs for poorly treated GERD patients for the health services were estimated 
to be c18 million for Spain, c12 million for Germany and c7 million for Italy. Absen-
teeism and presenteeism costs due to poorly controlled GERD for employers were 
almost none. CONCLUSIONS: Costs for complications in patients with poorly con-
trolled GERD added costs for health care systems for all three countries but almost 
no extra costs were found for employers.
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OBJECTIVES: To evaluate the cost-effectiveness of entecavir(ETV) vs.lamivudine(LVD) 
in the treatment of nucleoside-naive CHB patients and vs. adefovir(ADV) in LVD 
refractory CHB patients in Turkey. METHODS: A decision-tree model compared cost 
and effect of treating CHB patients over a 10-year period. Treatment effect in terms 
of viral load(VL) reduction predicted risk of long-term liver complications. Two CHB 
patient populations were studied: 1) nucleoside-naïve patients treated for 2 years with 
ETV(0,5 mg/day) vs. LVD(100 mg/day) and ADV as salvage therapy in case of LVD 
resistance; and 2)LVD- refractory patients treated for 10 years with ETV(1 mg/day) 
vs. ADV(10 mg/day). Effectiveness was measured as LYS and QALY. Efﬁ cacy data 
were obtained from pivotal trials, relative-risk estimations were derived from the 
R.E.V.E.A.L.-HBV Study cohort. a Turkish health care payer perspective was consid-
ered and a 3% discount rate was used for costs and outcomes. RESULTS: In the 
cohort of HBeAg(+/−) CHB patients, net incremental drug cost of ETV was higher 
compared to LVD. However, ETV was associated with a lower projected number of 
liver events (−73 and −55CC events, −43 and −33HCC events respectively, −8DC 
events in each cohort) compared with LVD. In nucleoside-naïve HBeAg(+) patients, 
ETV compared with LVD and ADV as salvage therapy gained 0.82LYS and 
0.68QALYs at an incremental cost of 5384TL(6571TL/LYS and 7865TL/QALY). In 
nucleoside-naïve HBeAg(-) patients, ETV generated 0.66LYS and 0.55QALY at an 
incremental cost of 7257TL(11039TL/LYS and 13,203TL/QALY). In LVD-refractory 
patients, ETV generated 0.48LYS and 0.40QALY with a saving of 14,117TL 
(−29,416TL/LYS and −35,178TL/QALY). CONCLUSIONS: This cost-effectiveness 
analysis suggests that in the Turkish health care system, ETV is a cost-effective treat-
ment option compared with LVD in the treatment of naïve CHB patients. In LVD 
refractory patients, ETV is a cost-saving treatment option relative to LVD with ADV 
as salvage therapy. Cost-beneﬁ ts with ETV therapy are explained lower overall CHB 
treatment costs due to slower disease progression rate and avoidance of resistance 
associated with LVD.
